ESC Professional Premium Access

Factor XIa inhibitors: a new approach to anticoagulation in patients with cardiovascular disease.

Congress Session

About the speaker

Doctor Jeffrey Weitz

Thrombosis & Atherosclerosis Research Institute (TaARI), Hamilton (Canada)
20 presentations
0 follower

5 more presentations in this session

Reversal agents to improve safety in patients treated with antiplatelet P2Y12 inhibitors.

Speaker: Professor D. Bhatt (Boston, US)

Thumbnail

Reversal agents to improve safety in patients treated with direct oral anticoagulants (DOACs).

Speaker: Associate Professor A. Niessner (Vienna, AT)

Thumbnail

P2Y12 inhibitor monotherapy in patients undergoing PCI.

Speaker: Doctor D. Angiolillo (Jacksonville, US)

Thumbnail

Injectable and intravenous P2Y12 inhibitors in patients with acute myocardial infarction.

Speaker: Professor G. Montalescot (Paris, FR)

Thumbnail

Problem-solving in antiplatelet therapy and anticoagulation – discussion.

Thumbnail

Access the full session

Problem-solving in antiplatelet therapy and anticoagulation

Speakers: Doctor J. Weitz, Professor D. Bhatt, Associate Professor A. Niessner, Doctor D. Angiolillo, Professor G. Montalescot
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk